CTLA4 and neuroblastoma: Compared with the group treated with PTT or anti-CTLA-4 checkpoint inhibitor alone, mice treated with this photothermal immunotherapy not only increased the survival rate by 43% or 55.5%, respectively, but also showed protection against neuroblastoma re-attack, suggesting the potential of PTT and ICIs in the treatment of brain tumors (106).